Background Patients with peripheral artery disease (PAD) are at very high risk of future
cardiovascular (CV) events. Strict lipid-lowering therapy is recommended. However, data on …

Background Low-density lipoprotein cholesterol (LDL-C) is associated with heightened risk
of major adverse cardiovascular events (MACE) and major adverse limb events (MALE) in …

Aims Due to a high burden of systemic cardiovascular events, current guidelines
recommend the use of statins in all patients with peripheral artery disease (PAD). We sought …

Background The ACC/AHA cholesterol guidelines recommend patients with peripheral
artery disease (PAD) be treated with a moderate to high‐intensity statin. The extent to which …

Background The risk of coronary artery disease in peripheral arterial disease (PAD) is high,
life prognosis is poor, and lipid-lowering treatment with statins has been reported to improve …

Background: Peripheral artery disease (PAD) affects more than 202 million people
worldwide. Several studies have shown that patients with PAD are often undertreated, and …

Peripheral arterial disease (PAD) is a strong risk factor for cardiovascular morbidity and
mortality. Therefore, target low-density lipoprotein (LDL) cholesterol level in patients with …

Peripheral artery disease (PAD) affects> 200 million people globally (1). Prior studies have
demonstrated that patients with PAD are at risk for cardiovascular and limb-related morbidity …

Abstract Purpose of Review There is a lack of consistency among the ACC/AHA and ESC
Guidelines on the treatment of patients with lower extremity PAD to a targeted LDL-c level. A …

Evidence suggests that statin therapy in patients with peripheral artery disease (PAD) is
beneficial yet use remains suboptimal. We examined trends in statin use, intensity, and …